Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »

Abstract Number: 2340 • 2015 ACR/ARHP Annual Meeting
Improvement in Treat to Target Serum Urate Levels: Preliminary Results from a Comparison Between Two Audits of Management
Fernando Perez-Ruiz^1,2, Mariano Andres³, Cesar Diaz-Torne⁴, Eugenio De Miguel⁵, Carmen Moragues⁶, Francisca Sivera⁷, Mercedes Jimenez⁸ and Carlos Alberto Sánchez-Piedra⁹, ¹BioCruces Health Research Institute, Baracaldo, Spain, ²Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ³Hospital de Alicante, Alicante, Spain, ⁴Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Rheumatology, University Hospital La Paz, Madrid, Spain, ⁶Rheumatology Division, Hospital Universitari Bellvitge, L´Hospitalet de Llobregat, Spain, ⁷Hospital de Elda, Alicante, Spain, ⁸Rheumatology Division, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁹Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: 1) assess the current quality of care in gout patients and 2) compare the current management with previous audit data. Methods: a second audit…
Abstract Number: 2342 • 2015 ACR/ARHP Annual Meeting
Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Michael Darley¹, Grant W. Cannon² and Christopher Jackson³, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: ACR guidelines exist for the management of gout including the use of uric acid-lowering therapy. ACR guidelines recommend routine monitoring of uric acid levels…
Abstract Number: 2343 • 2015 ACR/ARHP Annual Meeting
Impact of Colchicine Use on the Development of Incident Coronary Artery Disease
Susanna Jeurling¹, Daria Crittenden², Mark C. Fisher³, Binita Shah⁴, Steven P. Sedlis⁴, Craig T. Tenner⁵, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Rheumatology, NYU-HJD, New York, NY, ³Rheumatology, New York Univ-HJD, New York, NY, ⁴NYU School of Medicine, Division of Cardiology, New York, NY, ⁵Medicine, NYU School of Medicine, New York, NY, ⁶NYU School of Medicine, Division of Rheumatology, New York, NY, ⁷Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Patients with gout experience both inflammation and increased risk of cardiovascular disease (CVD). Studies suggest that colchicine reduces myocardial infarction (MI) risk, but whether…
Abstract Number: 2347 • 2015 ACR/ARHP Annual Meeting
Can We Predict the Dose of Allopurinol to Achieve Target Urate?
Dan Wright¹, Stephen Duffull¹, Tony R. Merriman², Nicola Dalbeth³, Murray Barclay⁴ and Lisa K. Stamp⁴, ¹School of Pharmacy, University of Otago, Dunedin, New Zealand, ²Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴Medicine, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Allopurinol is a first line urate lowering therapy in the management of gout. The observation that allopurinol hypersensitivity was associated with allopurinol dose, renal…
Abstract Number: 2353 • 2015 ACR/ARHP Annual Meeting
Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: A randomized, double-blind, placebo-controlled, Phase III clinical trial showed that lesinurad, a selective uric acid reabsorption inhibitor (SURI), in combination with febuxostat 80 mg…
Abstract Number: 2355 • 2015 ACR/ARHP Annual Meeting
Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Serum Uric Acid Levels: A Randomized Controlled Trial
Na Lu¹, Yuqing Zhang², Sharan K. Rai³, Gary C. Curhan⁴ and Hyon K. Choi⁵, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²BUSM, Boston, MA, ³Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Renal Division, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: There is a remarkable, increasing disease burden of gout and its associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% of cases in the US), underscoring…
Abstract Number: 2400 • 2015 ACR/ARHP Annual Meeting
Association Between Serum Urate and Osteoarthritis Progression in a Non-Obese Cohort
Svetlana Krasnokutsky¹, Mukundan Attur², Jonathan Samuels³, Fangfei Zhang⁴, Meng Chen⁴, Leon Ryback⁵, Steven B. Abramson⁶ and Michael H. Pillinger¹, ¹Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ²Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY, ³Rheumatology, NYU - Hospital for Joint Diseases, New York, NY, ⁴Medicine-Rheumatology, NYU School of Medicine-NYU Hospital for Joint Diseases, New York, NY, ⁵Radiology-Musculoskeletal Radiology, New York University School of Medicine-NYU Hospital for Joint Diseases, New York, NY, ⁶Dept of Rheumatology/Medicine, Hosp for Joint Diseases/NYU, New York, NY
Background/Purpose: We recently reported an association between gout and osteoarthritis (OA) presence and severity, and a possible association between hyperuricemia and OA severity (Howard et…
Abstract Number: 2407 • 2015 ACR/ARHP Annual Meeting
Comparison of Knee Osteoarthritis Treatment in the Non-Obese Versus Obese Populations Across Different Medical Specialties
Kelly Forrester¹, Farah Taufiq¹ and Jonathan Samuels^2,3, ¹NYU Langone Medical Center, New York, NY, ²Rheumatology, NYU - Hospital for Joint Diseases, New York, NY, ³Rheumatology, NYU Langone Medical Center, New York, NY
Background/Purpose: Knee osteoarthritis (KOA) in the obese population is underdiagnosed and routinely undertreated, as providers often attribute pain to excess weight without considering articular…
Abstract Number: 2511 • 2015 ACR/ARHP Annual Meeting
Primary Care Management of Patients with Rheumatic Diseases Prior to Rheumatologist Consultation
Jessica Widdifield¹, J Carter Thorne², Karen Tu³, Debra Butt³, Noah Ivers⁴, Claire Bombardier⁴, R. Liisa Jaakkimainen⁵, Vandana Ahluwalia⁶, J. Michael Paterson⁷ and Sasha Bernatsky⁸, ¹McGill University, Montreal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Preventive Med and Biostatisti, University of Toronto, Toronto, ON, Canada, ⁶Past President, Ontario Rheumatology Association, Brampton, ON, Canada, ⁷ICES, Toronto, ON, Canada, ⁸Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada
Background/Purpose: Primary care physicians (PCP) often play a central role in the early detection and referral for patients with rheumatic diseases. Our aim was to…
Abstract Number: 2791 • 2015 ACR/ARHP Annual Meeting
TREX-1 Variants in Sjögren’s Syndrome Related Lymphomagenesis
Panagiota Makri¹, Adrianos Nezos², Michael Voulgarelis³, Haralampos M. Moutsopoulos⁴ and Clio Mavragani⁵, ¹Physiology, Department of Physiology, School of Medicine, University of Athens, Athens, Greece, ²Physiology, Department of Experimental Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ³Pathophysiology, Department of Pathophysiology, Medical School of Athens, Athens, Greece, ⁴Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece, ⁵Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Three prime Repair Exonuclease 1 (TREX-1) is an exonuclease involved in DNA repair preventing genomic instability. TREX-1 variants have been previously associated with activation of type…
Abstract Number: 2815 • 2015 ACR/ARHP Annual Meeting
A Comparison of Th17 Gene Expression in Psoriatic Arthritis Synovial Fluid and Peripheral Blood
Fatima Abji¹, Remy Pollock², Kun Liang³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a destructive inflammatory arthritis that develops in approximately 30% of patients with cutaneous psoriasis. Th17 cells infiltrate psoriatic skin and…
Abstract Number: 2827 • 2015 ACR/ARHP Annual Meeting
Analysis of HLA-B27 Transgenic Rats Reveals Specific Gut Transcriptome and Microbiome Signatures Associated with Inflammation
Tejpal Gill¹, Mark Asquith², Stephen Brooks¹, James T. Rosenbaum³ and Robert A. Colbert⁴, ¹NIAMS/NIH, Bethesda, MD, ²OHSU, Portland, OR, ³Devers Eye Institute, Legacy Hospital system, Portland, OR, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: HLA-B27 and human beta 2-microglobulin expression in rats (transgenic; TG) induces a spontaneous inflammatory disease resembling human spondyloarthritis (SpA) with associated gastrointestinal inflammation. While…
Abstract Number: 2834 • 2015 ACR/ARHP Annual Meeting
CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients
Anastasiya Muntyanu¹, Fatima Abji², Kun Liang³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of patients with psoriasis. We previously identified C-X-C motif chemokine 10 (CXCL10) as…
Abstract Number: 3164 • 2015 ACR/ARHP Annual Meeting
Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population
Crystal Kleiber Balderrama¹, Daniel S. Lans², Ann K. Rosenthal^1,3 and Christie M. Bartels⁴, ¹Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, ³Division of Rheumatology, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Title: Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population. Background/Purpose: Precipitation of calcium pyrophosphate dihydrate (CPP) crystals in articular tissues…
Abstract Number: 2881 • 2014 ACR/ARHP Annual Meeting
The Center of Excellence in Musculoskeletal Care and Education: A Sustainable Interprofessional, Multidisciplinary Programmatic Innovation Developed with the Department of Veterans Affairs
Michael J. Battistone¹, Andrea M. Barker², Marissa Grotzke³, Peter Beck⁴, Jeffery Berdan⁵, Caroline Milne⁶, JoAnn Rolando⁷ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Division of Endocrinology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁴Orthopaedics, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁵Physical Medicine and Rehabilitation, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁷Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose While musculoskeletal (MSK) problems are common in primary care, the current formal education in the evaluation and management of these conditions is inadequate. Through…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].